Venous Thromboembolism Risk Markers and Discontinuing Combined Hormonal Contraceptives

Update: 2024-05-07

Description

In this episode, Contributing Editor Samuel Wilson, MD, an assistant professor of hematology at the University of North Carolina, Chapel Hill, talks with Marc Blondon, MD, an attending physician in the division of angiology and hemostasis with the University Hospitals of Geneva (Switzerland). They talk about a paper co-authored by Dr. Blondon titled, “Longitudinal profile of estrogen-related thrombotic biomarkers after cessation of combined hormonal contraceptives.” Dr. Wilson wrote about the study in a recent issue of The Hematologist.

Comments

Top Podcasts

The Best New Comedy Podcast Right Now – June 2024 The Best News Podcast Right Now – June 2024 The Best New Business Podcast Right Now – June 2024 The Best New Sports Podcast Right Now – June 2024 The Best New True Crime Podcast Right Now – June 2024 The Best New Joe Rogan Experience Podcast Right Now – June 20 The Best New Dan Bongino Show Podcast Right Now – June 20 The Best New Mark Levin Podcast – June 2024

In Channel

$DREAMMing of a Better Tomorrow: Belantamab-Based Triplet Therapy for Relapsed/Refractory Multiple Myeloma$

DREAMMing of a Better Tomorrow: Belantamab-Based Triplet Therapy for Relapsed/Refractory Multiple Myeloma

2024-12-2118:56

Haploidentical Stem Cell Transplantation Is an Acceptable Transformative Therapy for Young Adults With Sickle Cell Disease

2024-11-2723:43

Enhancing Risk Stratification for Pediatric B-Cell Acute Lymphoblastic Leukemia: No Longer a ‘PI’ in the Sky Idea?

2024-10-1118:11

A Leap of Faith? Elimination of Autologous Stem Cell Transplantation for Patients With Mantle Cell Lymphoma in First Remission

2024-09-1621:39

Anticoagulation Stewardship

2024-08-2925:56

Blood Global Hematology Editor-in-Chief Shares Vision

2024-07-1716:52

One on One With Dr. Fred Appelbaum

2024-06-2626:25

Genetic Switch System Suggests Targeting of Mutant JAK2 Reverses Myeloproliferative Neoplasms

2024-06-2123:49

Venous Thromboembolism Risk Markers and Discontinuing Combined Hormonal Contraceptives

2024-05-0725:41

Growing the Next Generation of Hematologists

2024-04-1520:14

Women in Hematology

2024-03-2626:39

Four Is Better Than Three: Will We Finally Agree?

2024-03-1823:18

Toward Equity in Access for ALL

2024-01-3026:42

The Brilliant Success of Blinatumomab for Babies With Acute Lymphoblastic Leukemia

2023-11-2916:13

Editors-in-Chief of Two New ASH Journals Share Their Visions

2023-10-2025:16

ASH’s Minority Recruitment Initiative Mentorship Program Offers a Win for All

2023-09-1814:20

Results From the Blood and Marrow Transplant Trials Network: How Should We Prevent Graft-versus-host Disease in 2023?

2023-09-0128:05

Genetic Background Influences the Growth of CHIP Clones Within the Bone Marrow, With Drs. Robert Hasserjian and Siddhartha Jaiswal

2023-07-0727:12

Drawing New Blood Into Hematology

2023-06-1631:39

Anticoagulation and Abnormal Uterine Bleeding: Acknowledging Calls to Action

2023-05-1825:13

00:00

Venous Thromboembolism Risk Markers and Discontinuing Combined Hormonal Contraceptives

#box-pro-ellipsis-173490943562131{-webkit-line-clamp:2;}Venous Thromboembolism Risk Markers and Discontinuing Combined Hormonal Contraceptives

Venous Thromboembolism Risk Markers and Discontinuing Combined Hormonal Contraceptives

The Hematologist

Venous Thromboembolism Risk Markers and Discontinuing Combined Hormonal Contraceptives